JPWO2021069700A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021069700A5 JPWO2021069700A5 JP2022521570A JP2022521570A JPWO2021069700A5 JP WO2021069700 A5 JPWO2021069700 A5 JP WO2021069700A5 JP 2022521570 A JP2022521570 A JP 2022521570A JP 2022521570 A JP2022521570 A JP 2022521570A JP WO2021069700 A5 JPWO2021069700 A5 JP WO2021069700A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- methoxyurea
- tetrahydrothieno
- difluorobenzyl
- dioxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913606P | 2019-10-10 | 2019-10-10 | |
| US62/913,606 | 2019-10-10 | ||
| PCT/EP2020/078475 WO2021069700A1 (en) | 2019-10-10 | 2020-10-09 | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551525A JP2022551525A (ja) | 2022-12-09 |
| JPWO2021069700A5 true JPWO2021069700A5 (enExample) | 2023-10-17 |
| JP7713934B2 JP7713934B2 (ja) | 2025-07-28 |
Family
ID=72852647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521570A Active JP7713934B2 (ja) | 2019-10-10 | 2020-10-09 | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220372044A1 (enExample) |
| EP (1) | EP4041738A1 (enExample) |
| JP (1) | JP7713934B2 (enExample) |
| CN (1) | CN115175912B (enExample) |
| WO (1) | WO2021069700A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019006227A2 (pt) | 2016-09-30 | 2019-06-18 | Myovant Sciences Gmbh | métodos de tratamento de leiomioma uterino e endometriose |
| US12441738B2 (en) | 2018-03-14 | 2025-10-14 | Assia Chemical Industries Ltd. | Solid state forms of Relugolix |
| WO2021069711A1 (en) | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea |
| JP2023549196A (ja) | 2020-11-11 | 2023-11-22 | ミオバント サイエンシズ ゲーエムベーハー | レルゴリクスの投与方法 |
| CN113620972A (zh) * | 2021-02-02 | 2021-11-09 | 奥锐特药业(天津)有限公司 | 瑞卢戈利新晶型及其制备方法 |
| WO2022214645A1 (en) | 2021-04-09 | 2022-10-13 | Farmhispania Group, S.L. | Processes and intermediates for the preparation of relugolix |
| WO2023066941A1 (en) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004207706B2 (en) * | 2003-01-29 | 2010-03-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| TWI508962B (zh) * | 2009-04-22 | 2015-11-21 | Du Pont | 氮雜環醯胺之固體形態 |
| BR112013009117A2 (pt) * | 2010-10-21 | 2016-07-19 | Biomarin Pharm Inc | sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo. |
| US20150099753A1 (en) * | 2012-05-11 | 2015-04-09 | Concert Pharmaceuticals Inc. | Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine |
| SMT202200255T1 (it) * | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| BR112019006227A2 (pt) * | 2016-09-30 | 2019-06-18 | Myovant Sciences Gmbh | métodos de tratamento de leiomioma uterino e endometriose |
| IL308528A (en) * | 2016-09-30 | 2024-01-01 | Takeda Pharmaceuticals Co | Treatment of prostate cancer |
| WO2019178304A1 (en) | 2018-03-14 | 2019-09-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of relugolix |
| EP3666776A1 (en) * | 2018-12-11 | 2020-06-17 | Sandoz AG | Hydrate of a gonadotropin-releasing hormone receptor antagonist |
| WO2020230094A1 (en) * | 2019-05-15 | 2020-11-19 | Dr. Reddy’S Laboratories Limited | Amorphous and crystalline forms of relugolix |
| CN111423452B (zh) * | 2020-03-26 | 2023-08-22 | 江西青峰药业有限公司 | 瑞卢戈利的中间体及其制备方法和应用 |
| CN111333633B (zh) * | 2020-04-01 | 2023-10-20 | 江西科睿药业有限公司 | 一种瑞卢戈利的中间体化合物及其制备方法和用途 |
| CN115947734A (zh) * | 2021-10-09 | 2023-04-11 | 江苏希迪制药有限公司 | 瑞卢戈利溶剂化物的晶型及其制备方法 |
-
2020
- 2020-10-09 CN CN202080082800.6A patent/CN115175912B/zh active Active
- 2020-10-09 EP EP20790251.1A patent/EP4041738A1/en active Pending
- 2020-10-09 JP JP2022521570A patent/JP7713934B2/ja active Active
- 2020-10-09 WO PCT/EP2020/078475 patent/WO2021069700A1/en not_active Ceased
-
2022
- 2022-04-08 US US17/716,965 patent/US20220372044A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5411734B2 (ja) | １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相 | |
| US5629331A (en) | Process for the preparation of a tetrazole derivative in two crystalline forms and novel the crystalline forms thereof | |
| JP5129132B2 (ja) | ４−メチル−ｎ−［３−（４−メチル−イミダゾル−１−イル）−５−トリフルオロメチル−フェニル］−３−（４−ピリジン−３−イル−ピリミジン−２−イルアミノ）−ベンズアミドの塩 | |
| JP4740115B2 (ja) | 置換ピラゾール | |
| AU2008206759B2 (en) | Nicotinic acetylcholine receptor modulators | |
| NL1026438C2 (nl) | Nieuwe verbindingen. | |
| CA2727680A1 (en) | 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer | |
| JP2012508719A (ja) | スニチニブマレートの新たな結晶形 | |
| CA2505361A1 (en) | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | |
| JP2007509043A5 (enExample) | ||
| JP2002521377A (ja) | ビフェニル誘導体 | |
| CA2194481A1 (en) | 2-ureido-benzamide derivatives | |
| JPWO2021069700A5 (enExample) | ||
| TW200800211A (en) | Pyrimidinyl-pyrazole inhibitors of aurora kinases | |
| JP2019510801A5 (enExample) | ||
| JP2022526827A (ja) | （ｅ）－３－［２－（２－チエニル）ビニル］－１ｈ－ピラゾールの固体形態 | |
| CA2612008A1 (en) | Bicyclic derivatives as p38 kinase inhibitors | |
| CN101312974A (zh) | 吡唑并异喹啉衍生物 | |
| JPWO2021069711A5 (enExample) | ||
| JPWO2023066941A5 (enExample) | ||
| WO2019119481A1 (zh) | 吲唑类衍生物激酶抑制剂 | |
| CN101611024A (zh) | 芳基-取代的吡唑-酰胺化合物的晶形 | |
| CN115385902B (zh) | 一种苯并咪唑类化合物及其制备方法和应用 | |
| JPH02292282A (ja) | キナゾリン誘導体及びその製造方法 | |
| WO2013064029A1 (zh) | 具有抗癌活性的苯甲酰脲衍生物及其制备方法和用途 |